NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...
Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, ...
Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.
Scientists have used AI to identify two novel subtypes of multiple sclerosis (MS), which could offer new, targeted treatments ...
Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...
MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...
BARCELONA, Spain — In a noninferiority trial in pediatric-onset multiple sclerosis (POMS), ocrelizumab met its primary endpoint compared with fingolimod, demonstrating better tolerability and greater ...
Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...
NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback